Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN) : a retrospective analysis of patients treated through an access program
Avtorji:ID Illini, Oliver (Avtor)
ID Hochmair, Maximilian J (Avtor)
ID Fabikan, Hannah (Avtor)
ID Weinlinger, Christoph (Avtor)
ID Tufman, Amanda (Avtor)
ID Swalduz, Aurélie (Avtor)
ID Lamberg, Kristina (Avtor)
ID Hashemi, Sayed M. S. (Avtor)
ID Huemer, Florian (Avtor)
ID Vikström, Anders (Avtor)
ID Mohorčič, Katja, Klinika Golnik (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (777,25 KB)
MD5: 4E4A25935572544E10543B5761550F3C
 
.pdf PDF - Priloga, prenos (108,37 KB)
MD5: FEC0A24230BF6F365D92D0FF838F908C
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their efficacy in the real-world setting is unknown. Methods: A retrospective efficacy and safety analysis was performed on data from RET fusio-%positive NSCLC patients who participated in a selpercatinib access program (named patient protocol) between August 2019 and January 2021. Results: Data from 50 patients with RET fusion-positive advanced NSCLC treated with selpercatinib at 27 centers in 12 countries was analyzed. Most patients were Non-Asian (90%), female (60%), never-smokers (74%), with a median age of 65 years (range, 38-89). 32% of the patients had known brain metastasis at the time of selpercatinib treatment. Overall, 13 patients were treatment-naïve, while 37 were pretreated with a median of three lines of therapy (range, 1-8). The objective response rate (ORR) was 68% [95% confidence interval (CI), 53-81] in the overall population. The disease control rate was 92%. The median progression-free survival was 15.6 months (95% CI, 8.8-22.4) after a median follow-up of 9 months. In patients with measurable brain metastases (n=8) intracranial ORR reached 100%. In total, 88% of patients experienced treatment-related adverse events (TRAEs), a large majority of them being grade 1 or 2. The most common grade >/=3 TRAEs were increased liver enzyme levels (in 10% of patients), prolonged QTc time (4%), abdominal pain (4%), hypertension (4%), and fatigue/asthenia (4%). None of patients discontinued selpercatinib treatment for safety reasons. No new safety concerns were observed, nor where there any treatment-related death. Conclusions: In this real-world setting, the selective RET-inhibitor selpercatinib demonstrated durable systemic and intracranial antitumor activity in RET fusion-positive NSCLC and was well tolerated.
Ključne besede:non-small cell lung carcinoma -- drug therapy -- genetics, molecular targeted therapy, real-world data, selpercatinib, targeted therapy, tyrosine kinase inhibitor
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Kraj izida:Velika Britanija
Založnik:Sage Journals
Leto izida:2021
Št. strani:str. 1-17
Številčenje:Vol. 13
PID:20.500.12556/DiRROS-14130 Novo okno
UDK:616-006
ISSN pri članku:1758-8359
DOI:10.1177/17588359211019675 Novo okno
COBISS.SI-ID:66935555 Novo okno
Avtorske pravice:© The Author(s), 2021.
Opomba:Nasl. z nasl. zaslona; Soavtorica iz Slovenije: Katja Mohorčič; Opis vira z dne 14. 6. 2021;
Datum objave v DiRROS:16.06.2021
Število ogledov:1989
Število prenosov:1040
Metapodatki:XML DC-XML DC-RDF
:
ILLINI, Oliver, HOCHMAIR, Maximilian J, FABIKAN, Hannah, WEINLINGER, Christoph, TUFMAN, Amanda, SWALDUZ, Aurélie, LAMBERG, Kristina, HASHEMI, Sayed M. S., HUEMER, Florian, VIKSTRÖM, Anders in MOHORČIČ, Katja, 2021, Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN) : a retrospective analysis of patients treated through an access program. Therapeutic advances in medical oncology [na spletu]. 2021. Vol. 13, p. 1–17. [Dostopano 23 marec 2025]. DOI 10.1177/17588359211019675. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=14130
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Therapeutic advances in medical oncology
Skrajšan naslov:Ther. adv. med. oncol.
Založnik:SAGE Publications
ISSN:1758-8359
COBISS.SI-ID:519822105 Novo okno

Licence

Licenca:CC BY-NC 4.0, Creative Commons Priznanje avtorstva-Nekomercialno 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc/4.0/deed.sl
Opis:Licenca Creative Commons, ki prepoveduje komercialno uporabo, vendar uporabniki ne rabijo upravljati materialnih avtorskih pravic na izpeljanih delih z enako licenco.
Začetek licenciranja:11.06.2021

Sekundarni jezik

Jezik:Ni določen
Ključne besede:nedrobnocelični karcinom pljuč -- terapija z zdravili -- genetika, molekularna tarčna terapija, podatki iz resničnega življenja, selperactinib, tarčna terapija, zaviralci tirozinskih kinaz


Nazaj